ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
Jabez heads for the clinic
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Pfizer drops its B7-H4 conjugate
Felmetatug vedotin’s exit could be bad news for Mersana.
